SCHEMBL23934214

SCHEMBL23934214

CN1C(=O)c2cc(NC(=O)c3ccc(C#N)cc3)cc(NC(=O)c3ccc(C#N)cc3)c2C1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
MAPT P10636 2/20 0.53
TP53 P04637 1/20 0.53
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
GPR35 Q9HC97 1/20 0.45
ESR1 P03372 1/20 0.45
RXFP1 Q9HBX9 2/20 0.43
MLYCD O95822 1/20 0.43
POLB P06746 1/20 0.43
TLK2 Q86UE8 1/20 0.43
KCNH2 Q12809 1/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
MMP1 P03956 1/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934284 0.88 MAPT (0.53) LMNAMAPTTP53MEN1KMT2A
SCHEMBL23934281 0.84 MEN1 (0.53) LMNAMAPTMEN1KMT2ANPC1
SCHEMBL23934265 0.82 POLB (0.50) LMNAMAPTTP53MEN1KMT2A
SCHEMBL27099899 0.78 POLB (0.41) MAPTTP53MEN1KMT2ARXFP1
SCHEMBL23934278 0.78 MAPT (0.54) LMNAMAPTMEN1KMT2ANPC1
SCHEMBL27099939 0.74 POLB (0.50) LMNAMAPTTP53MEN1KMT2A
SCHEMBL23934279 0.73 HPGD (0.43) LMNAMAPTTP53MEN1KMT2A
SCHEMBL6682415 0.72 MEN1 (0.60) LMNAMAPTMEN1KMT2ACYP11B1
SCHEMBL23934204 0.72 KDM4E (0.54) LMNAMAPTTP53MEN1KMT2A
SCHEMBL23934285 0.72 ACE2 (0.48) LMNAMAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 LMNA 4281/4885MAPT 1837/4885TP53 345/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 LMNA 4281/4885MAPT 1837/4885TP53 345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.